By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.

Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.